Skip navigation

Stay on the Pulse of Federal and State Reporting Requirements, Policy Initiatives and Strategic Best Practices for Implementation

September 18-19, 2019
  • Philadelphia, PA

Breaking News For Manufacturers: Wednesday, August 21st, 2019 — The Trump administration has officially filed an appeal putting list prices in TV drug ads back in play. This occurred just six weeks after a judge struck down its regulation requiring pharma companies to add the list price of a drug into its TV advertising days before being put into effect. The outcome? It is still uncertain what will occur next - Pharma will need to await a final ruling. Is your company prepared for this change?

Monday, July 8th, 2019 — A federal judge just ruled (days prior to the rule taking effect) that the Trump administration’s rule around drug price disclosure in DTC/television ads is unlawful. It has been deemed that the federal government does not have that level of governing authority over pharmaceutical manufacturers. This is a major shift in the transparency trend. An HHS person said that the agency will be working with the DOJ on “next steps related to the litigation.”

Friday, June 14th, 2019 — Amgen, Merck, Eli Lilly and the Association of National Advertisers sued the HHS for the final ruling that requires pharmaceutical list in DTC drug advertisements on television. Manufacturers are arguing that consumers do not pay the list price that would be advertised under the ruling making it unnecessary and a violation of the First Amendment.

Wednesday, May 8th, 2019 — The HHS formally announced its ruling requiring drug manufacturers to include list prices in television advertisements. This rule will go into effect 60 days after it is published in the Federal Register, which is expected to be Friday, May 10th. Pharma companies will need to comply to this ruling quickly. Impact on patients remains uncertain.

Join us in September to discuss the effects of this drug pricing transparency ruling.

In light of recent focus on HHS’s proposal to eliminate rebates, the final rule on drug pricing in DTC ads, the Senate Finance Committee hearing with pharma CEOs and a strong legislative movement towards transparency, there is a heightened focus on drug pricing transparency in the United States. Recent federal and state rulings create lingering questions around legislation and compliance complexities that will impact the market in real-time, causing uncertainty.

Join CBI’s 5th Edition Drug Pricing Transparency Congress to convene with stakeholders to forecast how these recent regulations will impact commercialization, reimbursement, pricing and compliance practices. Assess the advancements of legislation made in 2019, collaborate on scenario planning for the future and share best practices for implementation.

Don’t miss this timely update on state transparency laws — register today!

New For 2019!

  • Anticipate New State Legislations to Watch for 2020 —
    A Practical Analysis
  • Examine Trade Secret Protections for Compliance
  • Benchmarking Survey Results Reveal
  • TWO pre-conference workshops:
    • Drug Pricing Transparency Bootcamp —
      Key Considerations and Learnings For Reporting
    • Strategize for 2020 —
      Scenario Plan for the Possible Outcomes on Rebates
  • And more!

Speaker Perspectives From:

Bausch Health Biotechnology Innovation Organization (BIO)
Boehringer Ingelheim Celgene Covington & Burling LLP
Epstein Becker Green King & Spalding LLP Mallinckrodt Pharmaceuticals
Pharmaceutical Research and Manufacturers of America (PhRMA)
Porzio Life Sciences LLC Sanofi, Sidley Austin LLP

Back By Popular Demand:

  • State-By-State Analysis Showcase
    • Evaluate New State Legislations —
      Status Report on Washington and Maryland
    • Update on Existing Transparency Laws Including California and Oregon
  • Industry Talk — Set up an Internal Team to Respond to
    Drug Pricing Transparency Laws
  • State Drug Pricing Transparency Level-Set —
    Reporting and Requirements Landscape
  • Federal Spotlight —
    Status Update on Federal Initiatives for Transparency